205 related articles for article (PubMed ID: 21261591)
1. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
Coleman PJ; Cox CD; Roecker AJ
Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
[TBL] [Abstract][Full Text] [Related]
2. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
4. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
5. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
7. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
8. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S
Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
[TBL] [Abstract][Full Text] [Related]
9. Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.
Stasi LP; Artusi R; Bovino C; Buzzi B; Canciani L; Caselli G; Colace F; Garofalo P; Giambuzzi S; Larger P; Letari O; Mandelli S; Perugini L; Pucci S; Salvi M; Toro P
Bioorg Med Chem Lett; 2013 May; 23(9):2653-8. PubMed ID: 23535328
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.
Coleman PJ; Schreier JD; Roecker AJ; Mercer SP; McGaughey GB; Cox CD; Hartman GD; Harrell CM; Reiss DR; Doran SM; Garson SL; Anderson WB; Tang C; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Jul; 20(14):4201-5. PubMed ID: 20610153
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia.
Winrow CJ; Gotter AL; Cox CD; Tannenbaum PL; Garson SL; Doran SM; Breslin MJ; Schreier JD; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
Neuropharmacology; 2012 Feb; 62(2):978-87. PubMed ID: 22019562
[TBL] [Abstract][Full Text] [Related]
12. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
13. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
[TBL] [Abstract][Full Text] [Related]
14. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist.
Hirose M; Egashira S; Goto Y; Hashihayata T; Ohtake N; Iwaasa H; Hata M; Fukami T; Kanatani A; Yamada K
Bioorg Med Chem Lett; 2003 Dec; 13(24):4497-9. PubMed ID: 14643355
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.
Bettica P; Squassante L; Groeger JA; Gennery B; Winsky-Sommerer R; Dijk DJ
Neuropsychopharmacology; 2012 Apr; 37(5):1224-33. PubMed ID: 22237311
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists.
Coleman PJ; Schreier JD; McGaughey GB; Bogusky MJ; Cox CD; Hartman GD; Ball RG; Harrell CM; Reiss DR; Prueksaritanont T; Winrow CJ; Renger JJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2311-5. PubMed ID: 20207138
[TBL] [Abstract][Full Text] [Related]
17. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
18. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
19. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
[TBL] [Abstract][Full Text] [Related]
20. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
Perrey DA; German NA; Gilmour BP; Li JX; Harris DL; Thomas BF; Zhang Y
J Med Chem; 2013 Sep; 56(17):6901-16. PubMed ID: 23941044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
